Fate Therapeutics Inc (FATE)

[jondoeuk]

For (DTIL's) PBCAR19B (beginning at 2.7 × 108 with the ability to dose up to 8.1 × 108), it will be given following standard (not enhanced) LD chemo in R/R NHL. The first dose level of PBCAR19B is comparable to DL3 of the PBCAR0191A CAR-T therapy.

Also, they plan to test an ant-CD3 mAb https://www.businesswire.com/news/home/20210901006026/en/Precision-BioSciences-and-Tiziana-Life-Sciences-Announce-Exclusive-License-Agreement-to-Evaluate-Foralumab-a-Novel-Fully-Human-Anti-CD3-Monoclonal-Antibody-in-Conjunction-with-Allogeneic-CAR-T-Candidates-for-Cancer-Treatment